Drug Details

General Information of the Drug (ID: DR3755)
Name
Biphenyl dimethyl dicarboxylate
Synonyms
792-74-5; Dimethyl biphenyl-4,4'-dicarboxylate; dimethyl [1,1'-biphenyl]-4,4'-dicarboxylate; Biphenyl dimethyl dicarboxylate; DIMETHYL 4,4'-BIPHENYLDICARBOXYLATE; [1,1'-Biphenyl]-4,4'-dicarboxylic acid, dimethyl ester; methyl 4-(4-methoxycarbonylphenyl)benzoate; Nissel; UNII-K61BXA0U9C; 4,4'-Biphenyldicarboxylic acid, dimethyl ester; K61BXA0U9C; 4,4'-Bibenzoic Acid Dimethyl Ester; MFCD00017201; methyl 4-[4-(methoxycarbonyl)phenyl]benzoate; Dimethyl (1,1'-biphenyl)-4,4'-dicarboxylate; (1,1'-Biphenyl)-4,4'-dicarboxylic acid, dimethyl ester; (1,1'-Biphenyl)-4,4'-dicarboxylic acid, 4,4'-dimethyl ester; 1219803-50-5; [1,1'-Biphenyl]-4,4'-dicarboxylic acid, 4,4'-dimethyl ester; HSDB 5754; EINECS 212-341-4; PubChem8961; ACMC-209pgt; Maybridge1_001712; 4,4-Dicarboxymethylbiphenyl; 4,4'-Dicarbomethoxybiphenyl; SCHEMBL68521; MLS000720058; CHEMBL4297409; DTXSID2061143; HMS546F18; ZINC132343; 4,4'-Bis(methoxycarbonyl)biphenyl; 4,4'-bis (methoxycarbonyl)biphenyl; ANW-37275; CCG-45472; SBB005981; AKOS001588888; DB12475; Dimethyl biphenyl-4,4''-dicarboxylate; LS10548; MCULE-5377004782; AK121980; O731; SMR000304587; ST023391; SY057043; TS-00900; HY-128854; 4,4-Biphenyldicarboxylic acid dimethyl ester; B1309; CS-0100928; Dimethyl biphenyl-4,4'-dicarboxylate, 99%; FT-0625049; 4,4'-Biphenyldicarboxylic Acid Dimethyl Ester; 92D745; Biphenyl 4,4'-dicarboxylic acid, dimethyl ester; A839634; SR-01000397421; 4-(4-methoxycarbonylphenyl)benzoic acid methyl ester; SR-01000397421-1; SR-01000397421-2; W-111708; 4,4'-dimethyl [1,1'-biphenyl]-4,4'-dicarboxylate; BRD-K33126632-001-02-1; Q27281994; Dimethyl 4,4 inverted exclamation mark -Biphenyldicarboxylate; Dimethyl biphenyl-4,4 inverted exclamation marka-dicarboxylate; Dimethyl 4,4 inverted exclamation marka-Biphenyl-d8-dicarboxylate; Biphenyl-4'4-dicarboxylic acid dimethyl ester C16H14O4 270.29 212-216 degrees 792-74-5 212-341-4 MFCD00017201 Y
    Click to Show/Hide
Molecular Type
Small molecule
Disease Cholecystitis [ICD-11: DC12] Phase 3 [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C16H14O4
PubChem CID
13099
Canonical SMILES
COC(=O)C1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)OC
InChI
1S/C16H14O4/c1-19-15(17)13-7-3-11(4-8-13)12-5-9-14(10-6-12)16(18)20-2/h3-10H,1-2H3
InChIKey
BKRIRZXWWALTPU-UHFFFAOYSA-N
CAS Number
CAS 792-74-5
DrugBank ID
DB12475
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Ursodeoxycholic acid      Homo sapiens     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Up-regulation Activity STAT1  Molecule Info 
Pathway MAP
                    In-vitro Model Hep-G2 CVCL_0027 Hepatocellular carcinoma Homo sapiens
                    Experimental
                    Result(s)		 The inhibition of viral gene replication was enhanced by the combination of triple combination of amantadine, ursodeoxycholic acidbip, and henyl dimethyl dicarboxylate.
Target and Pathway
Target(s) Alanine aminotransferase 1 (ALT1)  Molecule Info  [3]
Alanine aminotransferase 2 (ALT2)  Molecule Info  [3]
References
Reference 1 ClinicalTrials.gov (NCT03578055) BDD With UDCA Therapy After Laparoscopic Cholecystectomy
Reference 2 The potential anti-hBV effect of amantadine in combination with ursodeoxycholic acid and biphenyl dimethyl dicarboxylate in hepG2 2.2.15 cells. Arch Pharm Res. 2005 Apr;28(4):451-7.
Reference 3 Diphenyl Dimethyl Bicarboxylate in the Treatment of Viral Hepatitis, Adjuvant or Curative?. Gastroenterology Res. 2008 Dec;1(1):2-7.
 Download Picture         KEGG Link